StockData
Artelo Biosciences, Inc. logo

Artelo Biosciences, Inc. (ARTL) stock

ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$1.68−0.02 (-1.18%)

Close on Nov 17, 2026Market cap $1.13MP/E –Yield –

Artelo Biosciences enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Artelo Biosciences's enterprise value was -$2.96M on Nov 11, 2026, against $71.36M a year earlier. Over the last 5 years it ranged from -$2.96M to $333.61M, with a median of $106.67M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$2.96M-106.0%
2025Dec 31, 2025$49.52M-43.4%
2024Dec 31, 2024$87.52M-18.0%
2023Dec 29, 2023$106.67M-9.2%
2022Dec 30, 2022$117.52M-64.8%
2021Dec 31, 2021$333.61M-77.4%
2020Dec 31, 2020$1.47B-59.8%
2019Dec 31, 2019$3.66B-43.8%
2018Dec 31, 2018$6.52B+42.2%
2017Dec 29, 2017$4.59B–

More Artelo Biosciences figures

See a number that looks wrong?